Abplatin(IV) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin
Abstract Background Cisplatin, the alkylating agent of platinum(II) (Pt(II)), is the most common antitumor drug in clinic; however, it has many side effects, therefore it is higly desired to develop low toxicity platinum(IV) (Pt(IV)) drugs. Multi-omics analysis, as a powerful tool, has been frequent...
Main Authors: | Xing Li, Lingpu Zhang, Tuo Li, Shumu Li, Wenjing Wu, Lingyu Zhao, Peng Xie, Jinqi Yang, Peipei Li, Yangyang Zhang, Haihua Xiao, Yingjie Yu, Zhenwen Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-022-01465-y |
Similar Items
-
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines
by: Elisabetta Gabano, et al.
Published: (2021-08-01) -
Development of Novel Pt(IV)-Carbohydrate Derivatives as Targeted Anticancer Agents against Osteosarcoma
by: Eoin Moynihan, et al.
Published: (2023-03-01) -
Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
by: Theresa Mendrina, et al.
Published: (2023-02-01) -
NIR and Reduction Dual-Sensitive Polymeric Prodrug Nanoparticles for Bioimaging and Combined Chemo-Phototherapy
by: Shuying Li, et al.
Published: (2022-01-01) -
Anticancer Activity, Reduction Mechanism and G-Quadruplex DNA Binding of a Redox-Activated Platinum(IV)–Salphen Complex
by: Vincenzo Vigna, et al.
Published: (2022-12-01)